Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases

被引：0
|
作者：
Chen, L. K. [1 ]
Yu, H. [1 ]
Chen, J. [1 ]
Li, M. [1 ]
Zhang, B. [1 ]
Zhang, B. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
nonesmall-cell lung cancer; brain metastases; immune checkpoint inhibitors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.03-42
引用
收藏
页码：S639 / S640
页数：2
相关论文
共 50 条
  • [1] Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy versus Bevacizumab Plus Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer with Brain Metastases
    Yu, Hui
    Chen, Jing
    Li, Meichen
    Zhang, Baishen
    Zhang, Bei
    Chen, Likun
    ADVANCED THERAPEUTICS, 2024, 7 (03)
  • [2] PD-1 Inhibitor Plus Chemotherapy as 2nd/Subsequent Line Setting Demonstrate Superior Efficacy Over PD-1 Inhibitor Alone in Pts of Advanced NSCLC
    Ren, S.
    Liu, Y.
    Zhou, F.
    Jiang, T.
    Su, C.
    Chen, X.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S458 - S459
  • [3] PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
    Tian, Zhichao
    Yao, Weitao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] Bevacizumab Plus Chemotherapy Cost Effectiveness
    Bordonaro, Roberto
    Cordio, Stefano
    Uccello, Mario
    Martines, Concetta
    Fassari, Giuseppina E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3840 - +
  • [5] Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer
    Xiong, Hui
    Li, Yun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (08): : 3559 - 3570
  • [6] PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
    Yu, Hui
    Chen, Ping
    Xia, Liangping
    Fu, Sha
    Chen, Chen
    Zhang, Xuanye
    He, Lina
    Zhang, Bei
    Zhou, Yixin
    Hong, Shaodong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [7] Genomic Correlates of Response to PD-1 Blockade Plus Chemotherapy in Patients with Untreated Advanced NSCLC
    Jiang, T.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S239 - S240
  • [8] Alectinib superior to chemotherapy in advanced ALK plus NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (06): : E285 - E285
  • [9] Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report
    Guo, Lihong
    Zhang, Jie
    Liu, Xueqin
    Liu, Haocong
    Zhang, Yamin
    Liu, Jinpeng
    ONCOTARGETS AND THERAPY, 2022, 15 : 629 - 636
  • [10] Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
    Cai, Hongfu
    Fang, Ling
    Lin, Jingwen
    Zheng, Zhiwei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345